These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Everson GT; Balart L; Lee SS; Reindollar RW; Shiffman ML; Minuk GY; Pockros PJ; Govindarajan S; Lentz E; Heathcote EJ Aliment Pharmacol Ther; 2008 Apr; 27(7):542-51. PubMed ID: 18208570 [TBL] [Abstract][Full Text] [Related]
26. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). Carreño V; Marcellin P; Hadziyannis S; Salmerón J; Diago M; Kitis GE; Vafiadis I; Schalm SW; Zahm F; Manzarbeitia F; Jiménez FJ; Quiroga JA Hepatology; 1999 Jul; 30(1):277-82. PubMed ID: 10385667 [TBL] [Abstract][Full Text] [Related]
27. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C. Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209 [TBL] [Abstract][Full Text] [Related]
28. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. Pol S; Couzigou P; Bourlière M; Abergel A; Combis JM; Larrey D; Tran A; Moussalli J; Poupon R; Berthelot P; Bréchot C J Hepatol; 1999 Jul; 31(1):1-7. PubMed ID: 10424277 [TBL] [Abstract][Full Text] [Related]
29. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial. Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074 [TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. Reichard O; Glaumann H; Frydén A; Norkrans G; Wejstål R; Weiland O J Hepatol; 1999 May; 30(5):783-7. PubMed ID: 10365802 [TBL] [Abstract][Full Text] [Related]
31. Effect of anti-viral therapy for occult hepatitis C virus infection. Pardo M; López-Alcorocho JM; Castillo I; Rodríguez-Iñigo E; Perez-Mota A; Carreño V Aliment Pharmacol Ther; 2006 Apr; 23(8):1153-9. PubMed ID: 16611276 [TBL] [Abstract][Full Text] [Related]
32. Histological response to interferon alfa-based therapies in hepatitis C. Lee SS Semin Liver Dis; 2004; 24 Suppl 2():55-60. PubMed ID: 15346247 [TBL] [Abstract][Full Text] [Related]
33. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570 [TBL] [Abstract][Full Text] [Related]
34. Short-term versus sustained response to interferon therapy: effect on histology. Reichard O Dig Dis Sci; 1996 Dec; 41(12 Suppl):109S-114S. PubMed ID: 9011467 [TBL] [Abstract][Full Text] [Related]
35. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. Yamada M; Fukuda Y; Koyama Y; Nakano I; Urano F; Katano Y; Hayakawa T J Gastroenterol Hepatol; 1996 Jul; 11(7):646-51. PubMed ID: 8840240 [TBL] [Abstract][Full Text] [Related]
36. Therapy of hepatitis C: patients with cirrhosis. Schalm SW; Fattovich G; Brouwer JT Hepatology; 1997 Sep; 26(3 Suppl 1):128S-132S. PubMed ID: 9305677 [TBL] [Abstract][Full Text] [Related]
37. Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients. Nirei K; Matsumura H; Kumakawa M; Matsumoto N; Nakamura H; Yamagami H; Matsuoka S; Moriyama M Int J Med Sci; 2017; 14(1):45-52. PubMed ID: 28138308 [No Abstract] [Full Text] [Related]
38. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Fernández I; Meneu JC; Colina F; García I; Muñoz R; Castellano G; Fuertes A; Abradelo M; Lumbreras C; Moreno E; Solís-Herruzo JA Liver Transpl; 2006 Dec; 12(12):1805-12. PubMed ID: 17133585 [TBL] [Abstract][Full Text] [Related]
39. Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy. Wang X; Gao F; Yuan G; Shi K; Huang Y; Chen Y; Qiu R; Sun L; Liu J; Hu C; Zhou Y J Viral Hepat; 2016 Dec; 23(12):971-976. PubMed ID: 27453300 [TBL] [Abstract][Full Text] [Related]
40. alpha-Interferon treatment of chronic hepatitis C in young patients with homozygous beta-thalassemia. Di Marco V; Lo Iacono O; Capra M; Grutta S; Ciaccio C; Gerardi C; Maggio A; Renda D; Almasio P; Pisa R Haematologica; 1992; 77(6):502-6. PubMed ID: 1289187 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]